Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema

Study Overview
=================
Brief Summary
-----------------
This study is to evaluate the expression of biological markers in induced sputum and peripheral blood T lymphocytes of patients with combined pulmonary fibrosis and emphysema (CPFE). The features of CPFE would be observed, including pulmonary function tests and fractional exhaled nitric oxide （FENO）.

Detailed Description
-----------------
A new disease including concomitant upper-lobe emphysema and lower-lobe fibrosis in radiology has been defined as (combined pulmonary fibrosis and emphysema, CPFE). CPFE has distinct clinical characteristics with the emphysema and the pulmonary fibrosis, including gender, age, clinical manifestation, pulmonary function tests and prognosis. Normally Th1/Th2 is balanced. However, patients with emphysema had a significantly higher expression of Th1. On the other hand, higher expression of Th2 is involved in the development of pulmonary fibrosis. The expressions of Th1 and Th2 were proved to play a central role in pathogenesis of emphysema and pulmonary fibrosis, while are still unknown in patients of combined pulmonary fibrosis and emphysema. The study would observe the Th1/Th2 expression, pulmonary function tests , fractional exhaled nitric oxide （FENO）and other features in CPFE patients.

Official Title
-----------------
Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema

Conditions
-----------------
Pulmonary Fibrosis, Emphysema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IPF-alone group: 10 patients meeting the IPF diagnosis criteria without emphysema. CPFE group: 15 patients with CT presentation of concomitant upper-lobe emphysema and lower-lobe fibrosis. Emphysema-alone group: 15 patients with their CT diagnosis of emphysema without fibrosis. Control: 20 healthy sex- and age-matched volunteers including nonsmokers and smokers. None of the healthy volunteers with a history of respiratory diseases. Exclusion Criteria: Age > 90 or < 50 Treated with corticosteroids or other immunomodulatory drugs Some known causes of interstitial lung disease such as collagen vascular disease, drug-induced lung disease, occupational disease. An exacerbation in 4 weeks Subjects had a history of allergic diseases.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Emphysema-alone<br> | |
| CPFE group<br> | |
| IPF-alone<br> | |
| smokers<br> | |
| nonsmokers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the expression of CXCR3 in blood by flow cytometry and the chemokine IL-4,IFN-γ,CXCL9,CXCL10,CXCL11 and CCL17 in sputum and blood |  | six months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pulmonary function tests |  | six months | 
| fractional exhaled nitric oxide （FENO） |  | six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
emphysema; pulmonary fibrosis;chemokine;sputum